Destabilase Lysozyme Activity
Lysozyme domain of destabilase — antimicrobial activity against peptidoglycan-containing bacteria.
Preclínico / mecanísticoLast updated: 2026-05-26 · Reviewed by ASH Editorial Board
Mechanistic Evidence Box
Preclinical / mechanistic- Page type
- Compound profile
- Evidence type
- Lysozyme domain of destabilase — antimicrobial activity against peptidoglycan-containing bacteria.
- Evidence level
- In vitro
- Drug vs leech
- Purified natural compound
Clinical translation limit
Destabilase's lysozyme activity against bacterial peptidoglycan is in vitro/mechanistic only and does not establish clinical efficacy as an antimicrobial. No FDA-approved derivative exists.
Molecular Profile
- Category
- Antimicrobial
- Evidence tier
- Preclinical
- Molecular weight
- 12,500 Da
- Source species
- Hirudo medicinalis
Biological Targets
- → bacterial peptidoglycan (β1,4 N-acetylmuramic acid — N-acetylglucosamine)
External Resources
Related Antimicrobial Compounds
Theromacin
Antimicrobial peptide active against Gram-negative bacteria — innate immunity of leech.
Theromyzin
Antimicrobial peptide; structural analogue of mammalian defensin family.
Macrostomin
Antimicrobial peptide active against Gram-positive bacteria — amphipathic alpha-helix.
Hirunipins
Newly-characterized antimicrobial peptide family (Kumar 2025) — candidate next-generation antibiotics against AMR pathogens.